Vnitr Lek 2012, 58(10):779-783

Effect of ivabradin on heart rate, left ventricular function a NT-proBNP concentration in patients with systolic chronic heart failure - case reports

F. Málek
Kardiovaskulární centrum Nemocnice Na Homolce Praha, přednosta prim. MUDr. ©těpán Černý, CSc.

Ivabradin is indicated in patients with compensated chronic heart failure and sinus rhythm with resting heart rate ≥ 75 beats per minute despite maximal tolerated beta-blocker dose. Three case reports show favourable effect of ivabradin therapy on heart rate, reverse cardiac remodeling and B-type natriuretic peptide concentration in patients with systolic heart failure.

Keywords: chronic heart failure; ivabradin; heart rate; cardiac remodeling; B-type natriuretic peptide

Received: June 12, 2012; Accepted: September 17, 2012; Published: October 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Effect of ivabradin on heart rate, left ventricular function a NT-proBNP concentration in patients with systolic chronic heart failure - case reports. Vnitr Lek. 2012;58(10):779-783.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Diaz A, Bourassa MG, Guertin MC et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974. Go to original source... Go to PubMed...
    2. Fox K, Ford I, Steg PG et al. BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction: a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-821. Go to original source... Go to PubMed...
    3. Flannery G, Gehrig-Mills R, Billah B et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865-869. Go to original source... Go to PubMed...
    4. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010; 376: 875-885. Go to original source... Go to PubMed...
    5. Ekman I, Chassany O, Komajda M et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011; 32: 2395-2404. Go to original source... Go to PubMed...
    6. Tardif JC, O'Meara E, Komajda M et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507-2515. Go to original source... Go to PubMed...
    7. ©pinar J, Vítovec J, Hradec J et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání České kardiologické společnosti 2011. Vnitř Lék 2012; 58 (Suppl 1): 1S4-1S40.
    8. McMurray JJ, Adamopoulos S, Anker SD et al. Task Force Members. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.